{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:06:14Z","timestamp":1788951974818,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clbc.2026.07.031","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:18:14Z","timestamp":1785701894000},"page":"179-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Expanded Access to Germline High Penetrance Genetic Testing for Women With a New Diagnosis of Invasive Breast Cancer or High-Grade DCIS"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9495-3827","authenticated-orcid":false,"given":"Sarah P.","family":"Hudson-Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akriti","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wadha","family":"Al Yaqout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Rusby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Krupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios Konstantinos","family":"Tasoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Merh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Torr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clbc.2026.07.031_bib0001","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12957-024-03553-9","article-title":"Understanding genetic variations associated with familial breast cancer","volume":"22","author":"Pal","year":"2024","journal-title":"World J Surg Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.031_bib0002","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in Nordic countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.clbc.2026.07.031_bib0003","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.annonc.2024.07.244","article-title":"Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing","volume":"35","author":"Rowlands","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.031_bib0004","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2","volume":"371","author":"Antoniou","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.031_bib0005","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41416-024-02832-2","article-title":"BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial","volume":"131","author":"Torr","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2026.07.031_bib0006","unstructured":"National Genomic Test Directory: Testing Criteria for Rare and Inherited Disease. Version 8.1; 2025. Available at: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2018\/08\/rare-and-inherited-disease-eligibility-criteria-V8.1.pdf."},{"issue":"2","key":"10.1016\/j.clbc.2026.07.031_bib0007","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","article-title":"Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer","volume":"340","author":"Hartmann","year":"1999","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.031_bib0008","first-page":"2272","article-title":"Oncoplastic breast surgery: a guide to good practice","volume":"47","author":"Gilmour","year":"2021","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"25","key":"10.1016\/j.clbc.2026.07.031_bib0009","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.031_bib0010","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.07.031_bib0012","unstructured":"National Genomic Testing Directory: Testing Criteria for Rare and Inherited Disease; 2024. Available at: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2024\/07\/national-genomic-test-directory-rare-and-inherited-disease-eligibility-criteria-v7.pdf."},{"key":"10.1016\/j.clbc.2026.07.031_bib0013","unstructured":"National Institute for Health and Care Excellence (NICE). (2023). Olaparib for Adjuvant Treatment of BRCA Mutation-Positive HER2-Negative High-risk Early Breast Cancer after Chemotherapy [Internet]. Available at: https:\/\/www.nice.org.uk\/guidance\/ta886."},{"issue":"9596","key":"10.1016\/j.clbc.2026.07.031_bib0014","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet Lond Engl"},{"issue":"10","key":"10.1016\/j.clbc.2026.07.031_bib0015","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1245\/s10434-016-5328-7","article-title":"Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for BRCA1\/BRCA2 mutation carriers with breast cancer","volume":"23","author":"Chiba","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.031_bib0016","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ygyno.2014.05.028","article-title":"Preoperative genetic testing affects surgical decision making in breast cancer patients","volume":"134","author":"Lokich","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clbc.2026.07.031_bib0019","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.breast.2022.12.001","article-title":"Does mainstream BRCA testing affect surgical decision-making in newly-diagnosed breast cancer patients?","volume":"67","author":"Ain","year":"2023","journal-title":"Breast Edinb Scotl"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.031_bib0017","article-title":"Timing of genetic testing in BRCA1\/2 and PALB2-associated breast cancer: preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy","volume":"50","author":"Apostolova","year":"2024","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.clbc.2026.07.031_bib0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13053-017-0071-z","article-title":"Preoperative genetic testing impacts surgical decision making in BRCA mutation carriers with breast cancer: a retrospective cohort analysis","volume":"15","author":"Yadav","year":"2017","journal-title":"Hered Cancer Clin Pract"},{"key":"10.1016\/j.clbc.2026.07.031_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94195-4","article-title":"Preoperative diagnosis of BRCA1\/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients","volume":"11","author":"Woo","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.031_bib0022","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1245\/s10434-023-14394-3","article-title":"Universal germline-genetic testing for breast cancer: implementation in a rural practice and impact on shared decision-making","volume":"31","author":"Shelton","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"10.1016\/j.clbc.2026.07.031_bib0023","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.031_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.31427","article-title":"Universal genetic testing for newly diagnosed invasive breast cancer","volume":"7","author":"Rezoug","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.031_bib0026","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.07.031_bib0024","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2147\/CLEP.S206949","article-title":"A systematic review of the international prevalence of BRCA mutation in breast cancer","volume":"11","author":"Armstrong","year":"2019","journal-title":"Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.031_bib0027","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41431-020-00783-9","article-title":"Examining the uptake of predictive BRCA testing in the UK; findings and implications","volume":"29","author":"Martin","year":"2021","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.031_bib0029","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1002\/cam4.5515","article-title":"Genetic testing women with newly diagnosed breast cancer: what criteria are the most predictive of a positive test?","volume":"12","author":"Metcalfe","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.clbc.2026.07.031_bib0028","article-title":"Population-based germline testing of BRCA1, BRCA2, and PALB2 in breast cancer patients in the United Kingdom: evidence to support extended testing, and definition of groups who may not require testing","volume":"2","author":"Evans","year":"2024","journal-title":"Genet Med Open"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.031_bib0030","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5694\/mja2.51906","article-title":"Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care","volume":"218","author":"De Silva","year":"2023","journal-title":"Med J Aust"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.031_bib0031","doi-asserted-by":"crossref","first-page":"359","DOI":"10.5694\/mja2.51916","article-title":"Moving breast cancer susceptibility gene testing into the mainstream","volume":"218","author":"Wong","year":"2023","journal-title":"Med J Aust"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.031_bib0032","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.annonc.2025.04.012","article-title":"Breast cancer germline multigene panel testing in mainstream oncology based on clinical\u2013public health utility: ESMO Precision Oncology Working Group recommendations","volume":"36","author":"Turnbull","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.031_bib0021","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.031_bib0033","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/jmedgenet-2020-107356","article-title":"Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers","volume":"59","author":"Marcinkute","year":"2022","journal-title":"J Med Genet"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.031_bib0034","article-title":"Risk-reducing mastectomy for the prevention of primary breast cancer","volume":"4","author":"Carbine","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"10.1016\/j.clbc.2026.07.031_bib0035","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-15-1465","article-title":"Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review","volume":"22","author":"Li","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.031_bib0036","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1245\/s10434-015-4532-1","article-title":"Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis","volume":"22","author":"De Felice","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.031_bib0037","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0002-9610(00)00505-5","article-title":"Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer","volume":"180","author":"Peralta","year":"2000","journal-title":"Am J Surg"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.031_bib0038","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjc.6602703","article-title":"Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers","volume":"93","author":"van Sprundel","year":"2005","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.031_bib0039","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","article-title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","volume":"19","author":"Copson","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2026.07.031_bib0040","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1200\/JCO-25-00834","article-title":"Survival outcomes with or without risk-reducing mastectomy in BRCA1 and BRCA2 pathogenic variant carriers","volume":"44","author":"Gandhi","year":"2026","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.031_bib43","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1001\/jamaoncol.2025.2203","article-title":"Defining lifetime risk thresholds for breast cancer surgical prevention","volume":"11","author":"Wei","year":"2025","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.031_bib0041","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.18486","article-title":"Clinical outcomes for BRCA pathogenic variant carriers with breast cancer undergoing breast conservation","volume":"7","author":"Wanis","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.031_bib0042","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.9840","article-title":"Long-term oncologic outcome of breast-conserving treatment in patients with breast cancer with BRCA variants","volume":"8","author":"Lee","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:07:16Z","timestamp":1788948436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926001333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1526820926001333"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.031","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Expanded Access to Germline High Penetrance Genetic Testing for Women With a New Diagnosis of Invasive Breast Cancer or High-Grade DCIS","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}